ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,781 | -5.0% | 1,162 | -9.5% | 0.00% | – |
| Q2 2023 | $114,554 | +5.1% | 1,284 | +26.3% | 0.00% | – |
| Q1 2023 | $108,993 | +3.8% | 1,017 | +18.0% | 0.00% | – |
| Q4 2022 | $105,000 | +6.1% | 862 | -9.2% | 0.00% | – |
| Q3 2022 | $99,000 | +22.2% | 949 | +9.0% | 0.00% | – |
| Q2 2022 | $81,000 | +6.6% | 871 | +33.8% | 0.00% | – |
| Q1 2022 | $76,000 | -16.5% | 651 | -3.7% | 0.00% | – |
| Q4 2021 | $91,000 | -71.1% | 676 | -65.9% | 0.00% | -100.0% |
| Q3 2021 | $315,000 | +14.5% | 1,980 | -5.5% | 0.00% | 0.0% |
| Q2 2021 | $275,000 | +1.1% | 2,095 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $272,000 | -11.7% | 2,112 | +14.7% | 0.00% | 0.0% |
| Q4 2020 | $308,000 | +15.8% | 1,841 | +6.5% | 0.00% | 0.0% |
| Q3 2020 | $266,000 | +28.5% | 1,729 | +23.1% | 0.00% | 0.0% |
| Q2 2020 | $207,000 | +1781.8% | 1,405 | +1264.1% | 0.00% | – |
| Q1 2020 | $11,000 | – | 103 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |